Literature DB >> 35622322

Quality Control for IG /TR Marker Identification and MRD Analysis.

Eva Fronkova1, Michael Svaton1, Jan Trka2.   

Abstract

Selection of the proper target is crucial for clinically relevant monitoring of minimal residual disease (MRD) in patients with acute lymphoblastic leukemia using the quantitation of clonal-specific immunoreceptor (immunoglobulin/T cell receptor) gene rearrangements. Consequently, correct interpretation of the results of the entire analysis is of utmost importance. Here we present an overview of the quality control measures that need to be implemented into the process of marker identification, selection, and subsequent quantitation of the MRD level.
© 2022. The Author(s).

Entities:  

Keywords:  Acute lymphoblastic leukemia; Minimal residual disease; Next-generation sequencing; PCR; Quality control

Mesh：

Substances：

Year:  2022        PMID： 35622322     DOI： 10.1007/978-1-0716-2115-8_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  11 in total

Review 1.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

Authors:  V H J van der Velden; A Hochhaus; G Cazzaniga; T Szczepanski; J Gabert; J J M van Dongen
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring.

Authors:  V H J van der Velden; J M Wijkhuijs; J J M van Dongen
Journal:  Leukemia       Date:  2007-09-13       Impact factor: 11.528

3.  ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data.

Authors:  Vojtech Bystry; Tomas Reigl; Adam Krejci; Martin Demko; Barbora Hanakova; Andrea Grioni; Henrik Knecht; Max Schlitt; Peter Dreger; Leopold Sellner; Dietrich Herrmann; Marine Pingeon; Myriam Boudjoghra; Jos Rijntjes; Christiane Pott; Anton W Langerak; Patricia J T A Groenen; Frederic Davi; Monika Brüggemann; Nikos Darzentas
Journal:  Bioinformatics       Date:  2017-02-01       Impact factor: 6.937

4.  Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.

Authors:  M J Pongers-Willemse; T Seriu; F Stolz; E d'Aniello; P Gameiro; P Pisa; M Gonzalez; C R Bartram; E R Panzer-Grümayer; A Biondi; J F San Miguel; J J van Dongen
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

5.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Authors:  V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

Review 6.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

7.  B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.

Authors:  E Fronkova; K Muzikova; E Mejstrikova; M Kovac; R Formankova; P Sedlacek; O Hrusak; J Stary; J Trka
Journal:  Bone Marrow Transplant       Date:  2008-05-19       Impact factor: 5.483

8.  Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.

Authors:  Henrik Knecht; Tomas Reigl; Michaela Kotrová; Franziska Appelt; Peter Stewart; Vojtech Bystry; Adam Krejci; Andrea Grioni; Karol Pal; Kamila Stranska; Karla Plevova; Jos Rijntjes; Simona Songia; Michael Svatoň; Eva Froňková; Jack Bartram; Blanca Scheijen; Dietrich Herrmann; Ramón García-Sanz; Jeremy Hancock; John Moppett; Jacques J M van Dongen; Giovanni Cazzaniga; Frédéric Davi; Patricia J T A Groenen; Michael Hummel; Elizabeth A Macintyre; Kostas Stamatopoulos; Jan Trka; Anton W Langerak; David Gonzalez; Christiane Pott; Monika Brüggemann; Nikos Darzentas
Journal:  Leukemia       Date:  2019-06-21       Impact factor: 11.528

9.  Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.

Authors:  Monika Brüggemann; Michaela Kotrová; Henrik Knecht; Jack Bartram; Myriam Boudjogrha; Vojtech Bystry; Grazia Fazio; Eva Froňková; Mathieu Giraud; Andrea Grioni; Jeremy Hancock; Dietrich Herrmann; Cristina Jiménez; Adam Krejci; John Moppett; Tomas Reigl; Mikael Salson; Blanca Scheijen; Martin Schwarz; Simona Songia; Michael Svaton; Jacques J M van Dongen; Patrick Villarese; Stephanie Wakeman; Gary Wright; Giovanni Cazzaniga; Frédéric Davi; Ramón García-Sanz; David Gonzalez; Patricia J T A Groenen; Michael Hummel; Elizabeth A Macintyre; Kostas Stamatopoulos; Christiane Pott; Jan Trka; Nikos Darzentas; Anton W Langerak
Journal:  Leukemia       Date:  2019-06-26       Impact factor: 11.528

10.  Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.

Authors:  Mathieu Giraud; Mikaël Salson; Marc Duez; Céline Villenet; Sabine Quief; Aurélie Caillault; Nathalie Grardel; Christophe Roumier; Claude Preudhomme; Martin Figeac
Journal:  BMC Genomics       Date:  2014-05-28       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.